“People have become more and more aware of social distancing in a generic sense, people don’t actually want to go to a busy pharmacy and queue with lots of unhealthy people,” he said “Another angle is the big uptake in e-ommerce and getting things delivered.”
Chemist2U is also set to see gains from the government’s e-prescribing framework which enables a shift from paper prescriptions to prescriptions using electronic QR codes.
“It’s being rolled out, all the infrastructure is built and adoption is still in early days but I think by the end of next year certainly it will increasingly be ubiquitous and paper prescriptions will progressively disappear,” Dr Cullen said.
Chemist2U will use the funding injection to target people with multiple prescriptions and invest in software development and marketing.
Craig Blair, co-founder and partner at AirTree Ventures, said Chemist2U was a “real disrupter” in the Australian marketplace and could benefit doctors, pharmacy owners and consumers.
“We have seen COVID, in particular, accelerate a whole range of improvements in health care delivery and really transformed everything from services to devices to products, and Chemist2U fits into that thematic,” he said. “It is going to be a very, very large market and I think there is room for lots of players.”
Start the day with major stories, exclusive coverage and expert opinion from our leading business journalists delivered to your inbox. Sign up here.